Literature DB >> 26896733

Predictive Factors for Reclassification and Relapse in Prostate Cancer Eligible for Active Surveillance: A Systematic Review and Meta-analysis.

Fausto Petrelli1, Ivano Vavassori2, Mary Cabiddu3, Andrea Coinu3, Mara Ghilardi3, Karen Borgonovo3, Veronica Lonati3, Sandro Barni3.   

Abstract

OBJECTIVE: To systematically evaluate the evidence on the predictors of the upgrading and biochemical recurrence of prostate cancer (PC) in those patients with low-risk disease assigned to active surveillance (AS).
MATERIALS AND METHODS: An electronic search of the PubMed, SCOPUS, Web of Science, CINAHL, Cochrane Library, Google Scholar, and Embase databases was performed for all reports that included detailed results of multivariate analyses of the predictors of PC reclassification and biochemical relapse during AS. Cumulative analyses of available hazard ratios (HRs) and their corresponding 95% confidence intervals were conducted using the RevMan 5.3 software to assess the potential predictors of PC upgrading and recurrence. Both random-effect model meta-analysis and Hartung-Knapp-Sidik-Jonkman meta-analysis method were applied to obtain the pooled HR for each covariate.
RESULTS: In the 32 articles analyzed, encompassing about 24,236 patients with early-stage PC, the 3 clinicopathological variables significantly associated with histological progression during AS were: prostate-specific antigen-density (HR 2.46; P = .0001); 2 positive cores (HR 1.54; P = .006); and race (HR 2; P = .04). Age, prostate-specific antigen levels, and suspicion on magnetic resonance imaging were not significantly associated with increased risk of progression of PC.
CONCLUSION: We identified 3 strong predictors for the upgrading of PC during AS. These should be systematically evaluated to enable patients with low-risk disease to be treated with AS.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26896733     DOI: 10.1016/j.urology.2016.01.034

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  4 in total

1.  Comparative analysis of 1152 African-American and European-American men with prostate cancer identifies distinct genomic and immunological differences.

Authors:  Walter Rayford; Alp Tuna Beksac; Jordan Alger; Mohammed Alshalalfa; Mohsen Ahmed; Irtaza Khan; Ugo G Falagario; Yang Liu; Elai Davicioni; Daniel E Spratt; Edward M Schaeffer; Felix Y Feng; Brandon Mahal; Paul L Nguyen; Robert B Den; Mark D Greenberger; Randy Bradley; Justin M Watson; Matthew Beamer; Lambros Stamatakis; Darrell J Carmen; Shivanshu Awasthi; Jonathan Hwang; Rachel Weil; Harri Merisaari; Nihal Mohamed; Leslie A Deane; Dimple Chakravarty; Kamlesh K Yadav; Kosj Yamoah; Sujit S Nair; Ashutosh K Tewari
Journal:  Commun Biol       Date:  2021-06-03

2.  Knowledge, attitudes, and practices of active surveillance in prostate cancer among urologists: a real-life survey from Brazil.

Authors:  Marcelo Langer Wroclawski; Breno Santos Amaral; Paulo Priante Kayano; Wilson Francisco Schreiner Busato; Sebastião José Westphal; Erik Montagna; Bianca Bianco; Andrey Soares; Fernando Cotait Maluf; Gustavo Caserta Lemos; Arie Carneiro
Journal:  BMC Urol       Date:  2022-06-15       Impact factor: 2.090

Review 3.  Importance of cost-effectiveness and value in cancer care and healthcare policy.

Authors:  Ravinder Kang; Philip P Goodney; Sandra L Wong
Journal:  J Surg Oncol       Date:  2016-06-22       Impact factor: 3.454

Review 4.  Active Surveillance in Intermediate-Risk Prostate Cancer: A Review of the Current Data.

Authors:  Leandro Blas; Masaki Shiota; Masatoshi Eto
Journal:  Cancers (Basel)       Date:  2022-08-27       Impact factor: 6.575

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.